BiogeniQ launches a pharmacogenetic test enabling patients diagnosed with ADHD to guide their treatment based on their genetics
Last modification : December 20, 2016
Montréal, September 20, 2016 — Today, BiogeniQ is launching the ADHD Pharma Profile, a personal pharmacogenetic test that evaluates the risk of side effects and non-response of over ten medications approved in Canada to treat attention deficit disorder with and without hyperactivity (ADD/ADHD).
One out of every three people diagnosed with ADHD does not respond appropriately to the first drug prescribed. What’s more, for 20% of people the second drug does not achieve the desired clinical response, and they are forced to continue their search for an effective treatment.[i]
The purpose of the ADHD Pharma Profile is to reduce the unwanted effects of this trial-and-error approach for patients who have been diagnosed with ADHD. Each person's DNA determines whether certain drugs are more likely to cause adverse side effects or be ineffective. Using a simple saliva test, the ADHD Pharma Profile evaluates seven genes and 11 molecules commonly used to treat ADHD.
In one to three weeks, the results specify which drugs are most likely to be incompatible at standard doses, based on their personalized profile. Upon request, the recommendations can also be sent to the patient’s physician, to set up a treatment plan that meets the patient's specific needs.
The non-prescription test can be purchased on the BiogeniQ website, in partner clinics and drug stores and at Biron Groupe Santé service points.
This is the first time a Canadian company has offered this type of innovative product. For more information, go to biogeniq.ca/en/our-products/adhd-profile.
Attention deficit disorder with and without hyperactivity is usually characterized by inattention, impulsivity and, in some cases, hyperactivity. Detection rates are rising and according to the CADDAC (Centre for ADHD Awareness, Canada), ADHD is under-diagnosed and under-treated[ii].
Pharmacogenetics is an emerging field that studies how genetic variations influence the response to drugs. Used as a clinical decision-making tool, pharmacogenetics increases the likelihood of effective treatment, reduces trial-and-error and the risk of unwanted side effects. Pharmacogenetic tests reduce drug-related uncertainty and interindividual variability.
BiogeniQ helps people take control of their health by providing simple, applicable, and relevant recommendations based on their DNA. By working closely with healthcare professionals, genetic testing related to nutrition, medication and certain diseases is delivered in a responsible, ethical way. Since its foundation in Montreal in 2013, BiogeniQ has won numerous healthcare and technology awards, and was named Tech Startup of the Year for 2016 by the RJCCQ (Québec Youth Chamber of Commerce). For more information, go to biogeniq.ca.
For more information:
[i] Agir ensemble pour mieux soutenir les jeunes – Trouble de déficit de l'attention/hyperactivité (TDAH). An action plan published by the Québec Ministry of Health and Social Services in June, 2000 http://publications.msss.gouv.qc.ca/msss/document-000493/, viewed September 2, 2016.